Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 64 | 3,173 | 37% |
| 2020 | 55 | 2,580 | 41% |
| 2021 | 52 | 2,442 | 47% |
| 2022 | 49 | 2,243 | 52% |
| 2023 | 56 | 2,238 | 55% |
| 2024 | 59 | 2,308 | 57% |
| 2025 from claims | – | 2,456 2,254–2,598 | 58% |
| 2026 forecast | – | 2,456 2,161–2,834 | 59% |
| 2027 forecast | – | 2,464 2,106–2,936 | 60% |
| 2028 forecast | – | 2,471 2,062–3,025 | 60% |
| 2029 forecast | – | 2,477 2,023–3,106 | 61% |
| 2030 forecast | – | 2,483 1,989–3,181 | 62% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 33% of the cases CMS names in Kentucky; 38 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 10% inpatient hospital, 87% hospital outpatient, 3% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 10,751−1.7%/yr | −1.7%/yr | 4.9 | 18% | 11,800 in 2030+1.5%/yr |
| Texas | 182 | 9,000−1.4%/yr | −1.4%/yr | 4.2 | 17% | 11,000 in 2030+3.4%/yr |
| North Carolina | 103 | 4,811−5%/yr | −5%/yr | 4.9 | 5% | 5,000 in 2030+0.6%/yr |
| Virginia | 111 | 4,758−1.7%/yr | −1.7%/yr | 4.6 | 25% | 4,870 in 2030+0.4%/yr |
| Georgia | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.5 | 17% | 5,540 in 2030+2.7%/yr |
| Tennessee | 110 | 4,594−3.3%/yr | −3.3%/yr | 6.6 | 25% | 4,840 in 2030+0.9%/yr |
| South Carolina | 83 | 4,214−0.8%/yr | −0.8%/yr | 6.2 | 7% | 4,820 in 2030+2.3%/yr |
| Maryland | 91 | 3,844−0.6%/yr | −0.6%/yr | 4.4 | 68% | 4,210 in 2030+1.5%/yr |
| Oklahoma | 58 | 2,956−0.1%/yr | −0.1%/yr | 6.1 | 1% | 3,150 in 2030+1.1%/yr |
| Mississippi | 43 | 2,629−1.4%/yr | −1.4%/yr | 7.1 | 30% | 2,760 in 2030+0.8%/yr |
| Alabama | 53 | 2,415−5.4%/yr | −5.4%/yr | 5.6 | 8% | 2,290 in 2030−0.9%/yr |
| Louisiana | 45 | 2,342−1%/yr | −1%/yr | 5.8 | 0% | 2,550 in 2030+1.4%/yr |
| Arkansas | 37 | 1,786−2.9%/yr | −2.9%/yr | 4.8 | 10% | 1,850 in 2030+0.6%/yr |
| West Virginia | 21 | 920−7.2%/yr | −7.2%/yr | 4.5 | 0% | 990 in 2030+1.3%/yr |
| Delaware | 19 | 805−2.9%/yr | −2.9%/yr | 4.7 | 31% | 860 in 2030+1.1%/yr |
| District of Columbia | 9 | 387+3.4%/yr | +3.4%/yr | 6.2 | 32% | 420 in 2030+1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 16 | 1,515−6.7%/yr | −6.7%/yr | 3.30.7× | 23% | 1,270 in 2030−2.9%/yr |
| Hysterectomy, hysteroscopy & ablation | 13 | 1,108−5.7%/yr | −5.7%/yr | 2.71.0× | 9% | 950 in 2030−2.6%/yr |
| Incontinence, prolapse & sacral neuromodulation | 10 | 902−8.4%/yr | −8.4%/yr | 2.00.7× | 11% | 950 in 2030+0.9%/yr |
| Prostatectomy & nephrectomy | 5 | 358−1.2%/yr | −1.2%/yr | 0.90.7× | 0% | 390 in 2030+1.4%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Florida
Calyxo leads with 70% of company spending on these surgeons in 2025, +19 pts on 2024.
In 2025, 4 companies reported engagement with Kentucky’s surgeons worth $9,029 in consulting, speaking, meals and travel tied to these products, about $153 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.